



March 2, 2017

## **GW Pharmaceuticals to Present at the Cowen and Company 37th Annual Healthcare Conference on Wednesday, 8 March, 2017**

LONDON, March 02, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Officer, will present at the Cowen and Company 37<sup>th</sup> Annual Healthcare Conference on Wednesday, 8 March, 2017 at 8:40 a.m. EST at the Boston Marriott Copley Place, Boston.

A live audio webcast of the presentation will be available through GW's corporate website at [www.gwpharm.com](http://www.gwpharm.com) on the Investors section under Events & Presentations. A replay will be available soon after the live presentation.

### **About GW Pharmaceuticals plc**

*Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit [www.gwpharm.com](http://www.gwpharm.com).*

Enquiries:

GW Pharmaceuticals plc  
Stephen Schultz, VP Investor Relations (U.S.)  
917 280 2424 / 401 500 6570